Mani Foroohar
Stock Analyst at Leerink Partners
(2.27)
# 2,745
Out of 4,981 analysts
167
Total ratings
49.45%
Success rate
-5.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Maintains: Underperform | $18 → $15 | $23.51 | -36.20% | 18 | Aug 22, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Market Perform | $45 → $10 | $17.39 | -42.50% | 2 | Jul 21, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Market Perform | $37 → $8 | $3.16 | +153.16% | 12 | May 28, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $19 → $18 | $5.18 | +247.49% | 3 | Mar 24, 2025 | |
| RXRX Recursion Pharmaceuticals | Maintains: Market Perform | $7 → $6 | $4.83 | +24.22% | 8 | Feb 28, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $31 → $27 | $6.81 | +296.48% | 9 | Jan 13, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $45 → $72 | $19.00 | +278.95% | 2 | Nov 12, 2024 | |
| CAMP Camp4 Therapeutics | Initiates: Outperform | $17 | $3.25 | +423.08% | 1 | Nov 5, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $47 → $49 | $74.31 | -34.06% | 11 | Oct 17, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $47 → $46 | $51.21 | -10.17% | 15 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $22 | $6.97 | +215.64% | 6 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $53 → $62 | $63.16 | -1.84% | 15 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $13.78 | -5.66% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $18.57 | +56.17% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $4 | $5.34 | -25.09% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $9.20 | - | 10 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $5.71 | +442.91% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.20 | +483.33% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $29.72 | +34.59% | 12 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $86 → $84 | $11.42 | +635.55% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $2.69 | +160.22% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $20.60 | +273.79% | 2 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $144 → $143 | $465.89 | -69.31% | 11 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $6.43 | -6.69% | 5 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $56.26 | +35.09% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $1.80 | +1,788.89% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $20 | $3.02 | +562.25% | 6 | Jul 23, 2021 |
Moderna
Aug 22, 2025
Maintains: Underperform
Price Target: $18 → $15
Current: $23.51
Upside: -36.20%
Sarepta Therapeutics
Jul 21, 2025
Downgrades: Market Perform
Price Target: $45 → $10
Current: $17.39
Upside: -42.50%
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Market Perform
Price Target: $37 → $8
Current: $3.16
Upside: +153.16%
Lexeo Therapeutics
Mar 24, 2025
Maintains: Outperform
Price Target: $19 → $18
Current: $5.18
Upside: +247.49%
Recursion Pharmaceuticals
Feb 28, 2025
Maintains: Market Perform
Price Target: $7 → $6
Current: $4.83
Upside: +24.22%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $6.81
Upside: +296.48%
Neurogene
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $19.00
Upside: +278.95%
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: $17
Current: $3.25
Upside: +423.08%
Mirum Pharmaceuticals
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $49
Current: $74.31
Upside: -34.06%
BridgeBio Pharma
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $46
Current: $51.21
Upside: -10.17%
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $6.97
Upside: +215.64%
Jul 24, 2024
Upgrades: Outperform
Price Target: $53 → $62
Current: $63.16
Upside: -1.84%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $13.78
Upside: -5.66%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $18.57
Upside: +56.17%
Apr 25, 2024
Downgrades: Market Perform
Price Target: $12 → $4
Current: $5.34
Upside: -25.09%
Mar 6, 2024
Upgrades: Outperform
Price Target: n/a
Current: $9.20
Upside: -
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $5.71
Upside: +442.91%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $1.20
Upside: +483.33%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $29.72
Upside: +34.59%
Jan 23, 2023
Maintains: Outperform
Price Target: $86 → $84
Current: $11.42
Upside: +635.55%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $2.69
Upside: +160.22%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $20.60
Upside: +273.79%
Jan 23, 2023
Maintains: Market Perform
Price Target: $144 → $143
Current: $465.89
Upside: -69.31%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $6.43
Upside: -6.69%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $56.26
Upside: +35.09%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $1.80
Upside: +1,788.89%
Jul 23, 2021
Maintains: Market Perform
Price Target: $50 → $20
Current: $3.02
Upside: +562.25%